Additionally, MDM2 inhibitor-nutlin3 can effectively repress RCC’S proliferation in vitro and vivo, which might be able to serve as an anti-tumor reagent potentially in TP53-WT RCC patient. The gene discussed is MDM2; the disease is renal cell carcinoma.